Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Indian Heart Journal, published by Elsevier, is a distinguished peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. Founded in 1961, this journal has been a pivotal resource for researchers, healthcare professionals, and students, providing a platform for innovative studies and insights into heart health. The journal transitioned to an Open Access model in 2013, ensuring widespread dissemination of vital research findings to enhance global understanding of cardiovascular diseases. Ranked in the Q3 category for Cardiology and Cardiovascular Medicine in 2023, it holds a reputable position in the medical community, with a Scopus rank of #222 out of 387 journals in the same field, placing it in the 42nd percentile. The Indian Heart Journal strives to foster advances in clinical practice and research while addressing the unique cardiac health challenges faced in India and beyond.

Expert Review of Precision Medicine and Drug Development, published by Taylor & Francis Ltd, is a valuable academic resource that thrives at the intersection of pharmacology, genetics, and molecular medicine. Since its inception in 2016, this journal has rapidly become a pivotal platform for researchers and practitioners aiming to advance the field of drug development through innovative precision medicine strategies. With a broad focus encompassing the latest advancements in drug discovery and genetic research, it operates within a competitive landscape, evidenced by its recent category quartile rankings where it holds Q4 in Drug Discovery, Genetics, and Molecular Medicine, alongside a Q3 ranking in Pharmacology for the year 2023. The journal offers a unique opportunity for scholars to share insights and foster collaborations that can lead to breakthroughs in therapeutic approaches. Although not an open-access journal, it maintains a commitment to disseminating outstanding research to a wide audience. By fostering a rigorous peer-review process, the journal aims to enhance the quality and impact of publications within these critical areas of medicine, making it an essential read for anyone involved in healthcare and pharmaceutical advancements.

The Journal of the American Heart Association, published by WILEY, serves as a premier platform for advancing cardiovascular medicine through its commitment to open access, fostering global dissemination of cutting-edge research since 2012. It proudly holds a prestigious position within the top quartile (Q1) in the categories of Cardiology and Cardiovascular Medicine, as evidenced by its Scopus ranking of #49 out of 387 journals, placing it in the 87th percentile. With a focus on innovative studies and transformative findings, this journal is essential for cardiologists, researchers, and healthcare professionals seeking to stay at the forefront of cardiovascular knowledge. The journal aims to bridge the gap between basic science and clinical practice, presenting findings that shape the future of heart health treatment and prevention. As a resource for academic and clinical communities alike, the Journal of the American Heart Association is dedicated to enhancing the understanding and treatment of cardiovascular diseases globally.

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

CURRENT OPINION IN CARDIOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is an esteemed journal in the field of cardiology that has been serving the academic community since 1988. With a robust focus on the latest developments and emerging trends in cardiovascular medicine, this journal aims to bridge the gap between clinical practice and research, offering critical insights and expert commentary. The journal is recognized in the medical community, achieving a 2023 Scopus rank of #148 out of 387 in its category, placing it in the 61st percentile. Although it operates under a subscription-based model, CURRENT OPINION IN CARDIOLOGY remains an essential resource for researchers, practitioners, and students seeking cutting-edge knowledge and advancements in cardiology. As a Q2 journal in the field, it continues to foster dialogue and provide a platform for disseminating impactful cardiovascular research, ultimately contributing to improved patient outcomes and informed clinical decisions.

Cardiogenetics, published by MDPI, is a leading open-access journal dedicated to advancing the field of genetics as it pertains to cardiovascular health and diseases. Since its launch in 2011, this journal has been at the forefront of disseminating high-quality research that explores the genetic underpinnings of cardiovascular conditions, offering a platform for innovative studies, reviews, and case reports. With an ISSN of 2035-8253 and an E-ISSN of 2035-8148, Cardiogenetics aims to bridge the gap between genetic research and clinical application, helping researchers, healthcare professionals, and students stay abreast of the latest advancements and findings. The journal’s commitment to open access ensures that its valuable content is available to a global audience, fostering greater collaboration and knowledge sharing in the cardiovascular genetics community. By contributing to this dynamic field, Cardiogenetics plays a crucial role in improving patient outcomes and paving the way for personalized medicine in cardiology.

Precision Clinical Medicine, published by Oxford University Press, is an esteemed open-access journal that has been at the forefront of clinical research since its inception in 2018. With an ISSN of 2096-5303, this journal specializes in the rapidly evolving field of precision medicine, which aims to tailor healthcare to individual patient characteristics, needs, and preferences. As a testament to its influence, Precision Clinical Medicine holds a remarkable rank of #34 out of 636 in the General Medicine category on Scopus, placing it within the 94th percentile of its field and earning a prestigious Q1 rating in 2023. Based in the United Kingdom, the journal not only provides open access content, ensuring that groundbreaking research is widely disseminated, but also serves as a crucial platform for innovations and discussions that shape modern medical practices. Researchers, professionals, and students alike will find valuable insights and influential studies that drive the future of personalized healthcare within its pages.

CARDIOLOGY, published by KARGER, is a renowned scholarly journal dedicated to the advancement of research in the fields of cardiology and cardiovascular medicine. Since its inception in 1937, the journal has consistently provided a platform for high-quality, peer-reviewed articles that contribute to the understanding and treatment of heart and vascular diseases. With an impressive convergence through 2024, CARDIOLOGY holds a respectable Q2 ranking in both the Cardiology and Cardiovascular Medicine and Pharmacology (medical) categories, placing it within the 53rd and 45th percentiles of respective Scopus ranks. Based in Switzerland, the journal serves as an essential resource for researchers and practitioners aiming to stay abreast of cutting-edge developments and evidence-based practices in cardiovascular health. While it currently does not offer open access options, its commitment to rigorous scientific standards solidifies its significance within the academic community. We invite readers to explore the latest research findings and contribute to this vital field through publications in CARDIOLOGY.

Current Genetic Medicine Reports, published by SPRINGERNATURE, is a prominent journal dedicated to advancing the field of genetic medicine. With an emphasis on the latest research and advancements, this journal serves as a critical platform for disseminating high-quality original articles, reviews, and reports that focus on the application of genetic information in various medical disciplines. As an open-access journal, it ensures that valuable findings are freely accessible to a global audience, thereby fostering collaboration and innovation among researchers, healthcare professionals, and students alike. Although the journal does not yet have an established impact factor, its commitment to rigorous peer review and its contributions to the understanding and integration of genetic medicine into clinical practice enhance its scholarly significance. The editorial board is comprised of leading experts, encouraging submissions that tackle contemporary issues in genetic research and its clinical applications. Located in London, England, this journal is poised to be a vital resource for those seeking to stay abreast of the rapid changes in the dynamic field of genetic medicine.